Blood-pressure-lowering peptide (LVYPFP)
A small natural peptide that blocks ACE, the enzyme that raises blood pressure; studied as a potential treatment for high blood pressure, but not an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
Literature-extracted sequence peptide — synthesized for bioassay as documented in linked reference(s)
Fork this card to add platform evidence →
Activity measured in linked reference(s) — IC50/MIC/cytotoxicity data
Fork this card to add platform evidence →
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could a single tiny protein fragment from milk hit both the enzyme behind high blood pressure and the enzyme behind high blood sugar?
If this holds, people with metabolic syndrome, where high blood pressure and type 2 diabetes often arrive together, might benefit from a single natural food ingredient instead of two separate drugs. It would not replace medication, but it could open a path to a functional dairy product with dual cardiometabolic support.
Is the blood-pressure-lowering activity of this peptide almost entirely due to a specific rigid shape created by two proline amino acids?
If the double-proline scaffold turns out to be the key, researchers could build smaller, cheaper, and more stable versions that keep the active shape without the full peptide. That could make future natural-origin blood pressure ingredients easier and less costly to develop.
Does this peptide target just one sub-unit of the blood pressure enzyme ACE, the way some newer prescription drugs do, rather than shutting the whole enzyme down?
Common prescription ACE inhibitors cause a persistent dry cough in roughly one in five people. If LVYPFP only blocks the part of ACE responsible for raising blood pressure, and leaves the other part alone, it might deliver antihypertensive benefit with less cough and fewer unwanted effects. That would be a meaningful advantage for a food-derived ingredient.
If you flip just the first building block of this peptide into its mirror-image form, does it last three times longer in blood without losing its activity?
Most food peptides break down quickly in blood before they can do anything useful. If a single stereochemical swap at one end of the molecule extends survival without touching the active part, it could transform a fragile food compound into a practical nutraceutical or pharmaceutical lead, at minimal added cost or complexity.
Is there already enough of this peptide in B. bifidum fermented milk to actually lower blood pressure in people with mildly elevated readings?
If a clinical study confirmed this, fermented dairy products could be positioned as a genuine dietary tool for stage-1 hypertension, something people could reach for without a prescription. Because fermented milk has a centuries-long safety record, the development pathway would be far shorter and cheaper than a drug.
Could this peptide also inhibit the enzyme that breaks down heart-protective hormones, the same dual-action mechanism behind the drug Entresto?
Entresto is one of the most effective heart-failure drugs approved in decades, and it works by blocking two enzymes simultaneously. If LVYPFP does the same thing naturally, it could open a genuinely new line of research into food-derived support for heart failure, not just blood pressure. This is a speculative but high-upside hypothesis worth testing.
Do we know the precise physical handshake between this peptide and the blood pressure enzyme it targets, and does that tell us anything useful about safety?
Understanding exactly how a molecule grabs its target, and which part of the enzyme it locks onto, helps predict side effects and guides smarter design of follow-on compounds. If the model is confirmed experimentally, it would give researchers a clear blueprint for improving the peptide or predicting how it differs from prescription ACE inhibitors in everyday use.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.8558291792869568 | boltz-2 |
| ranking score | 0.8963732123374939 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 1.014 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep04866,
sequence = {LVYPFP},
target = {ace},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}